Tirzepatide is a synthetic, modified incretin peptide analogue used in qualified laboratory research involving GIP and GLP-1 receptor signalling models. It is an acylated peptide with sequence modifications and is typically studied for multi-receptor peptide design and metabolic signalling pathway research.
Tirzepatide is a synthetic, modified incretin peptide analogue used in qualified laboratory research involving GIP and GLP-1 receptor signalling models. It is an acylated peptide with sequence modifications and is typically studied for multi-receptor peptide design and metabolic signalling pathway research. This material should be supplied strictly as a research compound and not as a medical product.
The following information is provided for research-catalogue and product specification purposes only. Batch-specific identity, purity, salt form and analytical values should be confirmed against the relevant Certificate of Analysis.
| What it is | Tirzepatide is a synthetic, modified incretin peptide analogue used in qualified laboratory research involving GIP and GLP-1 receptor signalling models. It is an acylated peptide with sequence modifications and is typically studied for multi-receptor peptide design and metabolic signalling pathway research. This material should be supplied strictly as a research compound and not as a medical product. |
|---|---|
| Sequence | Modified 39-amino-acid GIP analogue: Y-Aib-E-G-T-F-T-S-D-Y-S-I-Aib-L-D-K-I-A-Q-K-A-F-V-Q-W-L-I-A-G-G-P-S-S-G-A-P-P-P-S-NH2; Lys residue acylated with fatty-diacid linker. Verify final modified sequence against COA. |
| Molecular weight | 4813.53 g/mol |
| Product family | GIP / GLP-1 receptor peptide analogue |
| Research classification | Synthetic acylated peptide; incretin receptor signalling research compound |
| Form | Lyophilised powder |
| Appearance | White to off-white powder |
| Fill quantity | 10mg |
| Container type | Sterile sealed glass vial |
| Storage | Store dry, protected from light at -20°C. Avoid repeated freeze/thaw cycles after reconstitution. |
| Synonyms | Tirzepatide; LY3298176; dual GIP/GLP-1 receptor analogue |
| CAS number | 2023788-19-2 |
| Molecular form / formula | C225H348N48O68 |
| Molecule form | Modified acylated peptide; salt form COA-specific |
| Purity | Recommended product standard: >=98% by HPLC; confirm by batch COA |
| Analysis method | HPLC and LC-MS / MS confirmation |
Each compound is accompanied by third-party analytical documentation where available. Certificates confirm purity, identity and chromatographic analysis against the supplied batch.
Orders are typically processed within 1–2 business days of confirmed payment. Estimated delivery is 10–21 business days after dispatch, depending on destination and courier coverage. All shipping is tracked and discreetly packaged.
Store dry, protected from light at -20°C. Avoid repeated freeze/thaw cycles after reconstitution.
| Form | Lyophilised powder |
|---|---|
| Appearance | White to off-white powder |
| Container type | Sterile sealed glass vial |
| Storage & Handling | Store dry, protected from light at -20°C. Avoid repeated freeze/thaw cycles after reconstitution. |
All products are supplied by Greek Peptides for research use only. They are not licensed as pharmaceuticals and are not promoted as, or intended to diagnose, treat, cure, prevent or mitigate any disease or medical condition in humans or animals. They are not intended for human or animal consumption and are not intended for cosmetic, nutritional or recreational use.
By purchasing, the purchaser confirms that they are a qualified individual acting for legitimate research purposes only and accepts our Terms and Conditions and Research Use Policy.
